ASX ANNOUNCEMENT

Clinical progress for XanaMIA trial

Sydney, 21 June 2021. Actinogen Medical ASX: ACW ('ACW' or 'the Company') is pleased to announce that it has appointed leading clinical research organisations Avance Clinical ('Avance') and Paratus Clinical ('Paratus') to assist in the conduct, management, and recruitment of the XanaMIA Part A dose ranging study. Further, the Company has finalised its agreement with Australian neuroscience technology company Cogstate (ASX:CGS), to utilise its Neuropsychological Test Battery in the XanaMIA study.

The XanaMIA Part A study is to be conducted at four Paratus clinics in Australia and will enrol a total of 105 healthy volunteers aged 50 years and over in a dose ranging study of 5mg and 10mg Xanamem® doses, to confirm the minimum effective dose.

Avance, which will manage the XanaMIA study, is an Australian owned full-service Contract Research Organisation that specialises in supporting biotech companies with their early phase clinical trials. The total work order with Avance will be ~A$1.25m. Paratus, a provider of a clinical-trial site network and related services across Australia, will perform all subject recruitment activities, with a total budget of ~A$850k.

Actinogen finalised a work order with Cogstate in April for ~US$300k, to utilise its Neuropsychological Test Battery, a modern platform designed to deliver highly sensitive cognition tests.

As announced on 2 June 2021, Actinogen recently received Bellberry Human Research Ethics Committee approval for XanaMIA and is expected to commence enrolment of the first patients in July 2021.

ENDS

Actinogen Medical

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E: steven.gourlay@actinogen.com.au

Investor Enquiries

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: actinogen@vesparum.com

Announcement authorised by the Board of Directors of Actinogen Medical

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing an innovative treatment for cognitive impairment associated with neurological diseases amenable to modifications of raised cortisol levels inside brain cells. 'Cognition' relates to how a person understands and acts in the world around them. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.
Actinogen Medical's lead drug candidate, **Xanamem®,** has been specifically designed to block the production of cortisol – the stress hormone – in the brain. Chronically elevated cortisol is associated with cognitive decline in **Alzheimer's Disease**, potentially linked to cognitive impairment and anxiety in **Fragile X syndrome**, and cognitive impairment in neuropsychiatric diseases.

Xanamem offers a promising new approach to treat cognitive impairment associated with these neurological diseases. In the Company's recent XanaHES Phase I trial, Xanamem exhibited a statistically significant improvement in cognition among healthy older volunteers, and recent human target engagement data for the drug in the brain suggests good activity of doses as low as 5mg daily. The Company plans to initiate a range of Phase II studies evaluating Xanamem in

the treatment of cognitive impairment associated with Alzheimer's disease, Fragile X syndrome, and other indication(s) with a strong scientific rationale.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a registered trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.